Literature DB >> 14734458

Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines.

V Anne Westbrook1, Pamela D Schoppee, Alan B Diekman, Kenneth L Klotz, Margaretta Allietta, Kevin T Hogan, Craig L Slingluff, James W Patterson, Henry F Frierson, William P Irvin, Charles J Flickinger, Michael A Coppola, John C Herr.   

Abstract

PURPOSE: Members of the SPAN-X (sperm protein associated with the nucleus mapped to the X chromosome) family of cancer-testis antigens are promising targets for tumor immunotherapy because they are normally expressed exclusively during spermiogenesis on the adluminal side of the blood-testis barrier, an immune privileged compartment. EXPERIMENTAL DESIGN AND
RESULTS: This study analyzed the human SPANX genomic organization, as well as SPAN-X mRNA and protein expression in somatic and cancer cells. The SPANX family consists of five genes, one of which is duplicated, all located in a gene cluster at Xq27.1. From the centromere, the arrangement of the five SPANX genes mapped on one contiguous sequence is SPANXB, -C, -A1, -A2, and -D. Reverse transcription-PCR analyses demonstrated expression of SPAN-X mRNA in melanoma and ovarian cell lines, and virtual Northern analysis established SPANX gene expression in numerous cancer cell lines. Immunoblot analysis using polyclonal antisera raised against recombinant SPAN-X confirmed the translation of SPAN-X proteins in melanoma and ovarian tumor cell lines. The immunoreactive proteins migrated between M(r) 15,000 and M(r) 20,000 similar to those observed in spermatozoa. Immunoperoxidase labeling of melanoma cells and tissue sections demonstrated SPAN-X protein localization in the nucleus, cytoplasm, or both. Ultrastructurally, in melanoma cells with nuclear SPAN-X, the protein was associated with the nuclear envelope, a localization similar to that observed in human spermatids and spermatozoa. Significantly, the incidence of SPAN-X-positive immunostaining was greatest in the more aggressive skin tumors, particularly in distant, nonlymphatic metastatic melanomas.
CONCLUSIONS: The data herein suggest that the SPAN-X protein may be a useful target in cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734458     DOI: 10.1158/1078-0432.ccr-0647-3

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

1.  Expression of SpanX mRNA in testicular germ cell tumors.

Authors:  Michele Salemi; Aldo E Calogero; Paolo Bosco; Roberto Castiglione; Sandro La Vignera; Eugenia Borgione; Giancarlo Rappazzo; Enzo Vicari
Journal:  Hum Cell       Date:  2006-08       Impact factor: 4.174

2.  SPANX-B and SPANX-C (Xq27 region) gene dosage analysis in Down's syndrome subjects with undescended testes.

Authors:  Michele Salemi; Corrado Romano; Concetta Barone; Francesco Calí; Filippo Caraci; Carmelo Romano; Cataldo Scavuzzo; Francesco Scillato; Maria Grazia Salluzzo; Maria Piccione; Manuela Martines; Giovanni Corsello; Ferdinando Nicoletti; Paolo Bosco
Journal:  J Genet       Date:  2009-04       Impact factor: 1.166

3.  Exclusion of the 750-kb genetically unstable region at Xq27 as a candidate locus for prostate malignancy in HPCX1-linked families.

Authors:  Natalay Kouprina; Nicholas C O Lee; Adam Pavlicek; Alexander Samoshkin; Jung-Hyun Kim; Hee-Sheung Lee; Sudhir Varma; William C Reinhold; John Otstot; Greg Solomon; Sean Davis; Paul S Meltzer; Johanna Schleutker; Vladimir Larionov
Journal:  Genes Chromosomes Cancer       Date:  2012-06-26       Impact factor: 5.006

4.  Cancer-testis antigens: the current status on antigen regulation and potential clinical use.

Authors:  Seah H Lim; Yana Zhang; Jian Zhang
Journal:  Am J Blood Res       Date:  2012-01-01

5.  Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27.

Authors:  Natalay Kouprina; Adam Pavlicek; Vladimir N Noskov; Greg Solomon; John Otstot; William Isaacs; John D Carpten; Jeffrey M Trent; Joanna Schleutker; J Carl Barrett; Jerzy Jurka; Vladimir Larionov
Journal:  Genome Res       Date:  2005-11       Impact factor: 9.043

6.  A majority of the cancer/testis antigens are intrinsically disordered proteins.

Authors:  Krithika Rajagopalan; Steven M Mooney; Nehal Parekh; Robert H Getzenberg; Prakash Kulkarni
Journal:  J Cell Biochem       Date:  2011-11       Impact factor: 4.429

7.  SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth.

Authors:  Bertrand Fabre; Yongmei Feng; Ikrame Lazar; Ali Khateb; Patrick Turko; Julia M Martinez Gomez; Dennie T Frederick; Mitchell P Levesque; Lea Feld; Gao Zhang; Tongwu Zhang; Brian James; Jeny Shklover; Emily Avitan-Hersh; Ido Livneh; Marzia Scortegagna; Kevin Brown; Ola Larsson; Ivan Topisirovic; Haguy Wolfenson; Meenhard Herlyn; Keith Flaherty; Reinhard Dummer; Ze'ev A Ronai
Journal:  Mol Cancer Res       Date:  2020-06-22       Impact factor: 5.852

Review 8.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

9.  The SPANX gene family of cancer/testis-specific antigens: rapid evolution and amplification in African great apes and hominids.

Authors:  Natalay Kouprina; Michael Mullokandov; Igor B Rogozin; N Keith Collins; Greg Solomon; John Otstot; John I Risinger; Eugene V Koonin; J Carl Barrett; Vladimir Larionov
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

10.  Sperm-derived SPANX-B is a clinically relevant tumor antigen that is expressed in human tumors and readily recognized by human CD4+ and CD8+ T cells.

Authors:  Giovanni Almanzar; Purevdorj B Olkhanud; Monica Bodogai; Chiara Dell'agnola; Dolgor Baatar; Stephen M Hewitt; Claudio Ghimenton; Mohan K Tummala; Ashani T Weeraratna; Keith Sean Hoek; Natalay Kouprina; Vladimir Larionov; Arya Biragyn
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.